CASSIDY DICKSON: Open Payments
NPI 1609333947 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,002 in 51 payments from 17 companies in 2025. Trend: 2023 $1,228 · 2024 $1,884 · 2025 $1,002
Food & beverage: $1,002
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $279 |
| GENZYME CORPORATION | 4 | $123 |
| Celltrion USA Inc. | 6 | $106 |
| Janssen Biotech, Inc. | 5 | $96 |
| Madrigal Pharmaceuticals | 3 | $68 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $59 |
| Lilly USA, LLC | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Gilead Sciences, Inc. | 2 | $32 |
| Aimmune Therapeutics, Inc. | 2 | $28 |
Products named: DUPIXENT, VEGZELMA, TREMFYA, REZDIFFRA, LINZESS, CREON, XIFAXAN, OMVOH.
Industry payments across AL — which companies pay providers there.
